Floatz logo

Acm-Cpg

Appendiceal Adenocarcinoma

Brown UniversityPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Appendiceal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 3BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
MITOMYCIN C
City of Hope Medical Center
Phase 3B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2CCC
Apl-5125
Apollo Therapeutics Ltd
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Acm-Cpg is also rated in:

Malignant AscitesDormant
CC
Indicative ·
43 / 100
View asset →
peritoneum cancerDormant
CC
Indicative ·
43 / 100
View asset →
colorectal adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →